Medco Will Buy PolyMedica In $1.5 Billion Deal
This article was originally published in The Gray Sheet
Executive Summary
The pharmacy benefit manager Medco is expanding its foothold in the diabetes market with the $1.5 billion purchase of PolyMedica, a direct-to-consumer provider of diabetes supplies and services. The companies announced the definitive all-cash agreement Aug. 28 and expect the deal to close later this year
You may also be interested in...
Final Regulation Establishes Competitive Bidding For Durable Equipment
CMS will require certain medical supply manufacturers to begin submitting pricing bids to Medicare this month under a final 1regulation published April 2
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.